AGR2 and breast carcinoma: Elevated levels of extracellular AGR2 have been detected in sera, plasma, or urine of human cancer patients, including those with breast cancer, prostate cancer, urothelial carcinoma, nasopharyngeal carcinoma, and ovarian cancer [32, 41–45], showing a positive correlation with metastasis occurrence and poor prognosis.